

## Special Issue

# Vaccines against Infectious Diseases: Current Research and Future Perspectives

### Message from the Guest Editor

Novel vaccine platforms and delivery systems, including nucleic acid vaccines, viral-vectored vaccines and adjuvant-enhanced protein-based vaccines, have the potential to enhance immunity in clinical and preclinical studies. Despite this, generating robust de-novo immunity at mucosal surfaces, where a large portion of infections occur, remains a challenge. This Special Issue will focus on novel vaccine platforms, delivery systems, and the inclusion of adjuvants to enhance vaccine-induced immunity. We encourage the submission of research focusing on vaccine-induced immunity in clinical and preclinical models. We welcome the submission of original research and review articles that cover, but are not limited to, the following sub-topics:

- Development of clinical models that recapitulate age-associated changes in vaccine-induced immunity.
- Novel adjuvants and/or delivery methods that promote robust mucosal immune responses.
- Immunological characterization of the correlates of vaccine-induced immunity and protection in clinical or preclinical settings.

---

### Guest Editor

Dr. Ebony Gary

The Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104, USA

---

### Deadline for manuscript submissions

closed (30 November 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.9**  
**CiteScore 6.8**  
**Indexed in PubMed**



[mdpi.com/si/172266](https://mdpi.com/si/172266)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).